nogalamycin has been researched along with Neoplasm-Metastasis* in 2 studies
1 trial(s) available for nogalamycin and Neoplasm-Metastasis
| Article | Year |
|---|---|
Phase II trial of menogaril in advanced colorectal cancer.
Menogaril, a new semisynthetic anthracycline antibiotic, was administered to 35 patients with advanced colorectal cancer. The drug was infused over 2 hr at a dose of 160 mg/sqm or 200 mg/sqm repeated every 4 weeks. Twenty-seven patients were evaluable for response and no objective responses were achieved. Myelosuppression, only leukopenia, was usually of mild-moderate degree and occurred in 63% of the patients. Twenty-seven percent of the patients experienced severe leukopenia. Local erythema and phlebitis were frequently observed and were severe in 13% of the patients. Nausea/vomiting (66%) and alopecia (50%) were. of mild-moderate degree. This study suggests that menogaril at these doses and schedule had no activity in advanced colorectal cancer. Topics: Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Daunorubicin; Drug Administration Schedule; Drug Evaluation; Female; Hematologic Tests; Humans; Male; Menogaril; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Nogalamycin | 1988 |
1 other study(ies) available for nogalamycin and Neoplasm-Metastasis
| Article | Year |
|---|---|
Phase II evaluation of menogaril in women with metastatic breast cancer after failure of first-line chemotherapy.
A total of 25 patients with metastatic breast cancer who had failed one prior chemotherapy regimen and had not received prior treatment with doxorubicin were treated with menogaril (200 mg/m2 i.v. over 1 h) every 4 weeks. Four patients (16%) achieved partial regressions lasting a median of 46 days. The median time to progression for all patients was 60 days and the median survival was 264 days. Seventeen patients subsequently received doxorubicin after removal from protocol and six (35%) achieved objective regression. We conclude that menogaril administered by the method that we employed has marginal activity in women with metastatic breast cancer after failure of prior chemotherapy. Failure to respond to menogaril does not preclude response to subsequent treatment with doxorubicin. Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Daunorubicin; Drug Administration Schedule; Drug Evaluation; Female; Humans; Menogaril; Neoplasm Metastasis; Nogalamycin | 1988 |